B

Bright Minds Biosciences Inc
CNSX:DRUG

Watchlist Manager
Bright Minds Biosciences Inc
CNSX:DRUG
Watchlist
Price: 59 CAD 4.8% Market Closed
Market Cap: 263.4m CAD
Have any thoughts about
Bright Minds Biosciences Inc?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of DRUG.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DRUG Relative Value
Base Case
Not Available
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.6
Industry
23
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-1.8
Industry
23.4
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-1.8
Industry
27.3
vs History
0
vs Industry
59
Median 3Y
1.3
Median 5Y
1.4
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
28
Median 3Y
-0.2
Median 5Y
-0.3
Industry
4.3
vs History
vs Industry
27
Median 3Y
-0.2
Median 5Y
-0.3
Industry
3.8
vs History
vs Industry
30
Median 3Y
-0.2
Median 5Y
-0.4
Industry
6
vs History
vs Industry
26
Median 3Y
-0.2
Median 5Y
-0.4
Industry
3.8
vs History
vs Industry
71
Median 3Y
-15.6
Median 5Y
-33.5
Industry
4.8

Multiples Across Competitors

DRUG Competitors Multiples
Bright Minds Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Bright Minds Biosciences Inc
CNSX:DRUG
263.4m CAD 0 -74.1 -72.9 -71.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
301B USD 5.4 59.2 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
162B USD 5 38.3 17.8 33.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 12 -265.7 26.9 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD 4.1 916 10.2 10.2
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
138B AUD 6 33.9 20.9 26
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD 6.4 19 17.5 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
CA
B
Bright Minds Biosciences Inc
CNSX:DRUG
Average P/E: 213.3
Negative Multiple: -74.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.2
412%
US
Amgen Inc
NASDAQ:AMGN
38.3
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.7
42%
US
Gilead Sciences Inc
NASDAQ:GILD
916
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CA
B
Bright Minds Biosciences Inc
CNSX:DRUG
Average EV/EBITDA: 18
Negative Multiple: -72.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CA
B
Bright Minds Biosciences Inc
CNSX:DRUG
Average EV/EBIT: 23.4
Negative Multiple: -71.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
26
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top